The clarity of ocular optics and the availability of effective ophthalmic imaging technologies makes learning about brain disorders by viewing the retina very attractive. This is particularly true for Alzheimer disease (AD), for which many clinical trials have failed to reach end points, and it is agreed that understanding and treating at earlier stages of the disease is the road forward. Imaging of tissue-level changes that occur before clinically detectable cognitive impairment is a long-sought goal. In this issue of JAMA Ophthalmology, O’Bryhim and colleagues1 used optical coherence tomography angiography (OCT-A) to view AD retina and thus addressed a topic that is timely and important in its potential to reduce the projected societal burden of this neurologic disorder.
Curcio CA. Viewing Retinal Vasculature in Alzheimer Disease. JAMA Ophthalmol. 2018;136(11):1249–1250. doi:10.1001/jamaophthalmol.2018.3569
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: